Astrocytic tumors are the most common and the most malignant primary tumors of the central nervous system. We had previously observed that gastrin could signi®-cantly modulate both cell proliferation and migration of astrocytoma cells. We have investigated in the present study which genes could be targeted by gastrin in tumor astrocyte migration. Using a subtractive hybridization PCR technique we have cloned genes dierentially overexpressed in human astrocytoma U373 cells treated or not with gastrin. We found about 70 genes overexpressed by gastrin. Among the genes overexpressed by gastrin, we paid particular attention to tenascin-C, S100A6 and MLCK genes because their direct involvement in cell migration features. Their gastrin-induced overexpression was quantitatively determined by competitive RT ± PCR technique. We also showed by means of a reporter gene system that S100A6 and tenascin-C respective promoters were upregulated after gastrin treatment. These data show that gastrin-mediated eects in glioblastoma cells occur through activation of a number of genes involved in cell migration and suggest that gastrin could be a target in new therapeutic strategies against malignant gliomas. Oncogene (2001) 20, 7021 ± 7028.
Introduction
Astrocytic tumors are the most common primary tumors of the central nervous system and certainly the most aggressive (Legler et al., 1999; Kleihues and Cavenee, 2000) . The two major hallmarks of the malignant phenotype in high-grade astrocytic tumors (i.e. World Health Organization (WHO) grade III {anaplastic astrocytomas} and WHO grade IV {glio-blastomas}) associating them with dismal prognoses (Legler et al., 1999; Kleihues and Cavenee, 2000; Decaestecker et al., 1998) are the disrupted control of their cell proliferation and the ability of tumor astrocytes to diusely in®ltrate the normal brain parenchyma (Kleihues and Cavenee, 2000) . To signi®cantly improve this dismal prognosis, both the proliferation and the migration levels of tumor astrocytes have to be signi®cantly slowed down. Conventional chemotherapy and radiotherapy are ineective for the treatment of high-grade astrocytic tumors. We believe that a gastrinbased therapy could represent an interesting approach for the following reasons. Gastrin-related peptides (like cholecystokinin, CCK) constitute the most abundant peptide system in the brain and, vice versa, the brain is the main CCK production site (Rehfeld and Van Solidge, 1991) . We have already shown that gastrin is able to modify not only the cell proliferation level in human glioblastomas (Camby et al., 1994 (Camby et al., , 1996 , but also their level of migration (DeHauwer et al., 1998) . De la Fuente's group has also evidenced the eect of gastrin on the migration features of various cells of the immune system (De la Fuente et al., 1997 Fuente et al., , 1998 . Previous studies have shown that peptides related to gastrin family induce actin stress ®bers assembly (Taniguchi et al., 1996) . These modi®cations could be mediated by distinct molecular elements belonging to speci®c signaling cascades (Seuerlein et al., 1995; Stepan et al., 1999a,b) . Gastrin can act on the Sisinducible element (SIE), the serum response element (SRE) and the Ca 2+ /cAMP response element (CRE), all of which regulating elements of the c-fos promoter (Stepan et al., 1999b) . The activation of the SRE involves the small GTP-binding protein RhoA and the gastrin targets the c-fos promoter CarG sequence via the RhoA dependent pathways that play major roles in the cell motility processes (Lauenburger and Horwitz, 1996; Klemke et al., 1998; Maekawa et al., 1999) . In ®broblasts, for example, Cdc42 triggers the formation of ®lopodia, Rac1 regulates the formation of lamellipodia, and RhoA triggers the assembly of focal contacts and stress ®bers (Tapon and Hall, 1997) . Most of the Rho-interacting proteins include the myosin-binding subunit (MBS) of myosin light chain kinase (MLCK); increased MLCK phosphorylation could be a major contribution to the eects of Rho on actin organization (Lamb et al., 1988, Goeckeler and Wysolmerski, 1995) .
Tumor astrocytes use speci®c components of the extracellular matrix (ECM) to migrate (Gladson, 1999) . In addition to laminin (Giese et al., 1994) , myelin (Giese et al., 1996a) and ®bronectin (Enam et al., 1998) , tumor astrocytes also use the N-CAM neural adhesion molecule (Sasaki et al., 1998) , tenascin-C (Giese et al., 1996b) and a number of glycoproteins including a central segment of the NG2 proteoglycan (Burg et al., 1997) and the brain-enriched hyaluronan binding (BEHAB)/brevican gene product (Zhang et al., 1998) in their migration. Of all these ECM components tenascin-C is expressed only by tumor astrocytes from malignant gliomas, and not by normal astrocytes (Gladson, 1999) . Lastly, we recently showed that some S100 calcium-binding proteins belonging to the EF-hand family (SchaÈ fer and Heizmann, 1996; Donato, 1999) could also be involved in the migration of highly malignant astrocytic tumors (Camby et al., 1999) .
The aim of this study was therefore to investigate whether gastrin is able to up-regulate genes speci®cally involved in glioblastoma cell proliferation and/or migration.
Results

Isolation of genes differentially over-expressed after gastrin treatment in human U373 glioblastoma cells
We used subtractive hybridization PCR to construct a cDNA forward library containing clones corresponding to the genes dierentially over-expressed in the G17-treated U373 cells as compared to the cells left untreated. Dierential screening enabled us to eliminate falsely positive cases and to sequence those cDNA clones which were genuinely over-expressed. We chose to sequence the clones that hybridized to the forward-subtracted probe but not to the reverse-subtracted one, and also the clones that hybridized to both subtracted probes, but with much greater intensity to the forward-subtracted one (data not shown). This should correspond to a signi®cant over-expression of a gene under test conditions. Of the 187 clones analysed, the dierential screening revealed 73 worth sequencing.
Sequencing of the clones from the differential screening
A comparison of the sequences obtained by dierential screening against database sequences was performed for 53 dierent clone cDNAs. For the remaining clones either poor quality or double sequences were obtained. The results of the BLAST analysis are shown in Table 1 . In total 33 sequences, (62% of those analysed) correspond to previously characterized genes and 20 (38%) to uncharacterized genes (present in the EST database or totally new). Of the previously characterized genes, seven are linked to cell motility, three are involved in cell proliferation and the remaining 23 play roles in metabolism and transport, as detailed in Table 1 .
G17-induced increase of S100A6, tenascin-C and MLCK mRNAs
A quantitative competitive RT ± PCR approach was used to con®rm and quantify the over-expression of the speci®c genes involved in cell motility (Figure 1 ). The quanti®cation of mRNA ( Figure 2A ) revealed that 24 hours of gastrin treatment at 10 78 M increased S100A6 mRNAs from *3 500 copies/ng to *30 000 copies/ng (i.e. 850% increase). A similar induction of tenascin-C mRNA accumulation was seen in the G17-treated U373 cells ( Figure 2B ). Indeed, gastrin treatment increased tenascin-C messengers from *8 200 copies/ ng to *29 000 copies/ng. These data thus indicated that gastrin increased the tenascin-C gene expression in U373 glioblastoma cells by 350%. As shown in Figure  2C , the G17 exposure of the U373 cells induced a 190% increase in the Myosin Light Chain Kinase (MLCK) mRNA level (*8 600 copies/ng of total RNA) as compared to control (*4 500 copies/ng).
G17 activates the full-length S100A6 promoter and specific responsive elements upstream of the tenascin-C promoter
We investigated whether the S100A6 and the tenascin-C overexpression could be explained by the upregulation of the gene transcription via the activation of their respective promoters. To this end, transient expression experiments were performed by transfecting full-length S100A6 and (71175, +79) tenascin-C promoters fused to the CAT reporter gene. As shown in Figure 3 , G17 at 10 78 M was sucient to induce a full-length S100A6 promoter construct with a more or less twofold increase when compared to control. The G17 treatment of U373 cells transfected with pTN1175-CAT construct induced a too weak expression of the CAT reporter gene to enable us to de®nitively conclude to a G17-induced activation of the tenascin-C promoter gene ( Figure 4A ). However, previous studies state that the human tenascin-C promoter contains silencer elements between 7221 and 72271 (Gherzi et al., 1995) ; this is the reason why the pTN220-CAT construct, previously evidenced as more active than the longer sequence, was tested. The results showed an increase of 36% in CAT expression ( Figure 4B ). No consensus AP1 site was present in the fragment overlapping (7220, +79) sequences but two potential binding sites were detected, namely a GCN4 site at position 7146 with the sequence T 1 G 2 A 3 G 4 T 5 G 6 , and the NF-kB consensus sequence (G 1 R 2 G 3 R 4 N 5 N 6 Y 7 Y 9 Y 10 ) at position 7210 with the sequence GGGAATTCCT. It is known that c-Jun can transactivate by binding to the GCN4 binding domain. An interaction between c-Jun and the p65 subunit of the transcription factor NF-kB has been described, and the synergy of these two transcription factors has been previously shown to induce transactivation of the tenascin-C promoter without the presence of a AP1 sequence at 7875 (Mettouchi et al., 1997) . A (7865 to +38) tenascin-C promoter fused to the luciferase reporter gene was used to determine whether the ®rst 220 bp upstream of the tenascin-C gene contained responsive elements exhibiting optimal activation following G17-treatment, or whether other responsive elements localized upstream of 7220 bp could potentiate activation of the promoter. This plasmid contains a binding site for the zinc ®nger transcription factor Krox-20 at position 7230, and a putative binding site for AP2 at position 7385. The results showed an activation of the promoter with respect to results observed with pTN220-CAT ( Figure 4C ), where there was neither drastic potentiation nor inhibition. These results do not imply that Krox-20 and AP2 responsive elements are major regulators of tenascin-C expression in U373 cells. 
Discussion
The major hallmark of the malignant phenotype in high-grade astrocytic tumors (which prevents surgery and adjuvant therapies from being ecient) is the marked ability of the tumor astrocytes to migrate into the surrounding brain parenchyma (Legler et al., 1999; Kleihues and Cavenee, 2000; Decaestecker et al., 1998) . Since we had observed that gastrin is able to signi®cantly modulate the migration of human glioblastoma cells (DeHauwer et al., 1998) , in our present study we have investigated some of the molecular mechanisms by which gastrin could modulate this glioblastoma cell motility. We chose the U373 human glioblastoma cell line as an experimental model because we have already shown that close biological similarities exist between this experimental glioblastoma and highgrade human astrocytic tumors obtained directly from surgical resections (Kruczynski et al., 1995; Camby et al., 2001) . We made use of the PCR-subtraction hybridization technique to clone genes dierentially over-expressed in gastrin-treated U373 cells as compared to untreated cells. Our results showed ®rstly that, apart from genes involved in metabolic pathways, gastrin increased the expression of some genes involved in cell proliferation features (prohibitin, p102 gene and HSJ2 gene associated with PTTG oncogene), and secondly, that gastrin was able to increase the expression of several genes de®nitely involved in cell motility, including RhoA, Rac1b, S100A6, MLCK, Scar and tenascin-C.
The tenascin-C gene is thus one of the genes selectively over-expressed in gastrin-treated U373 glioblastoma cells (as compared to what happened in the case of untreated cells). To con®rm and to evaluate Figure 3 Expression of the 2A9 promoter-CAT. U373 cells were transfected with 10 mg of each plasmid and treated with TPA (100 ng/ml), G17 (10 78 M) for 6 h. Chloramphenical acetyltransferase and luciferase activity were detected as described in the Materials and methods section. Columns=means of three separate experiments, each performed in triplicate this over-expression, mRNA quanti®cation was carried out. A dramatic over-expression of the tenascin-C gene under gastrin treatment was revealed. This overexpression is a consequence of the speci®c activation of the tenascin-C gene promoter by gastrin, as demonstrated in gene reporter assays. This gastrininduced eect could be mediated by c-Jun and NF-kB, which have previously been shown to act synergistically to transactivate the tenascin-C promoter in primary rat embryo ®broblasts (Mettouchi et al., 1997) . The distribution of tenascin-C at the invasive edge of malignant gliomas, and even surrounding solitary invading cells, strongly suggests a role for this protein as a regulator of glioma cell migration (Treasurywala and Berens, 1998) . However, in contrast to the response to other matrix proteins, glioma cells migrating on tenascin-C do not follow a characteristic dose-dependent pattern since tenascin-C can act as both a permissive (at low densities) and a nonpermissive (at high densities) motility substrate (Treasurywala and Berens, 1998; Giese et al., 1996b) . Thus, the gastrin-induced decrease in human glioblastoma cell motility we reported previously (DeHauwer et al., 1998) could be mediated, at least in part, through a dramatic gastrin-induced increase in tenascin-C expression leading to non permissive densities and consequently to a decrease in cell motility.
As regards the speci®c elements of the signaling cascades involved in cell migration, we identi®ed RhoA and Rac1b as potential candidate genes whose expression could also be modulated by gastrin. RhoA and Rac1b are small GTPases which bind and hydrolyze guanosine nucleotides, so unmasking the structural domains by which GTPases can bind to their target proteins (AspenstroÈ m, 1999). These small GTPases control the assembly and disassembly of the actin cytoskeleton in response to extracellular signals, including interactions between integrins and extracellular matrix components or between growth factors and their receptors (Lauenburger and Horwitz, 1996; AspenstroÈ m, 1999) . In fact, Rho regulates the myosin light chain phosphatase while Rho and Rac control the synthesis of phosphatidylinositol 4,5-biphosphate, two activities that might help to explain the eects of these GTPases on the actin cytoskeleton (Maekawa et al., 1999; Tapon and Hall, 1997 ). All the substrates described so far for these kinases are components of the cytoskeleton as well as of MBS (the myosin-binding subunit of the myosin phosphatase) and the MLCK (myosin light chain kinase), both of which regulate the activity of myosin II.
The messenger RNA quanti®cation we carried out revealed an overexpression of the MLCK gene in gastrin-treated U373 glioblastoma cells as compared to untreated cells. Taken together, our data strongly suggest that gastrin markedly up-regulates both RhoA and MLCK gene expression. The dramatic gastrininduced overexpression of the MLCK gene product should be accompanied by marked actin contraction, a feature which can lead to a decrease in cell motility when the level of actin contraction is too high (Lauenburger and Horwitz, 1996) .
Previous studies show that Rho-dependent contraction of ®broblasts could be blocked by`contraction inhibitors' such as the MLCK inhibitor KT5926 (Chrzanowska-Wodnicka and Burridge, 1996) . Recent reports also used KT5926, and show that this compound is able to inhibit glioblastoma cell migration (Gillespie et al., 1999) . Our data suggest that gastrinbased therapies could therefore also be considered to control glioblastoma cell migration at the level of expression of the MLCK gene.
Data from the present study also emphasize the gastrin-induced overexpression of the Scar gene product, which is also under RhoA control. The Scar protein, which is a Wiskott-Aldrich syndrome-related protein (WASp), activates the nucleation of the Arp2/3 complex, which links the pointed ends of the actin ®laments (Machesky et al., 1999) . The combination of Scar and the Arp2/3 complex strongly stimulates the spontaneous assembly of monomeric actin (Machesky et al., 1999) . The dierential presence of Scar messengers in U373 cells treated with gastrin (in comparison to untreated cells) provides evidence that cell motility modulation by gastrin could be accompanied by the automatic assembly of the branched A B C Figure 4 Expression of several tenascin-C promoter constructs: pTN1175-CAT (A), pTN220-CAT (B) and pTN865-Luc (C). U373 cells were transfected with 10 mg of each plasmid and treated with TPA (100 ng/ml) if a TRE sequence was present, G17 (10
for 6 h. Chloramphenical acetyltransferase and luciferase activity were detected as described in the Materials and methods section. Columns=means of three separate experiments, each performed in triplicate actin network after the activation of the WASp/Scar family following the direct activation of the Scar gene transcription. Lastly, our data reveal that, as con®rmed by S100A6 mRNA quanti®cation, gastrin induces overexpression the S100A6 gene in the human U373 glioblastoma cells. As for tenascin-C, the over-expression of the S100A6 gene is a consequence of the speci®c activation of the S100A6 gene promoter, as demonstrated in the gene reporter assays. S100A6 belongs to the S100 family of calcium-binding protein, which is involved in the Ca 2+ -dependent regulation of a variety of intracellular activities including cell proliferation and dierentiation, intracellular Ca 2+ homeostasis and in¯ammation and protection from oxidative cell damage (SchaÈ fer and Heizmann, 1996; Donato, 1999) . S100 proteins are also involved directly in the dynamic control of the actin cytoskeleton (SchaÈ fer and Heizmann, 1996; Donato, 1999) by modulating the activity of distinct tropomyosin isoforms (Golitsina et al., 1996) , by direct linking to actin (Takenaga et al., 1994) , or by modifying the microtubule cytoskeleton (SchaÈ fer and Heizmann, 1996; Donato, 1999) which, in turn, modi®es the organization of the actin cytoskeleton (WatermanStorer and Salmon, 1999). We showed recently that the level of expression of S100A6 protein relates directly to the level of malignancy in human astrocytic tumors (Camby et al., 1999) . Thus, the gastrin-induced overexpression of the S100A6 gene product, observed in the present study, suggests that glioblastoma cell motility could also be modulated by gastrin at the level of S100 proteins expression, at least S100A6.
In conclusion, the present study reveals that the gastrin-induced modi®cations that we reported previously with respect to human glioblastoma cell motility occur via the gastrin-induced overexpression of a number of genes whose products have already proved to act directly on cell migration. These genes include: tenascin-C, whose product is an ECM component that decreases glioblastoma cell migration when secreted at high densities; RhoA; MLCK and Scar, whose products markedly modulate the organization of the actin cytoskeleton, as, indeed, is also the case for the S100A6 gene product. The data from the present study were obtained from subtraction cloning, which provides an alternative method for the identi®ca-tion of genes playing key roles under speci®c conditions. The genes that we identi®ed here as being overexpressed in human glioblastoma cells under gastrin treatment could represent potential candidates for new therapeutic strategies against malignant gliomas.
Materials and methods
Compounds and cell cultures
Gastrin-17 (pGlu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-GluAla-Tyr-Gly-Trp-Met-Asp-Phe-NH 2 ) was synthesized in our laboratory (Montpellier, France) and was further puri®ed by means of high-pressure liquid chromatography (HPLC).
The human astrocytic tumor cell line U373 was obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). The cells were cultured at 378C in a humidi®ed atmosphere containing 5% CO 2 and were grown in MEM (Gibco, Belgium) supplemented with 5% FCS, 0.6 mg/ml glutamine (Gibco), 200 IU/ml Penicillin and 200 m/ml streptomycin (Gibco). The cultures were routinely fed every 3 ± 4 days with fresh medium and subcultured once a week.
Subtractive hybridization and differential screening
As described previously (DeHauwer et al., 1998) , 25 million U373 cells were incubated for 72 h either in the presence or in the absence of 5 nM gastrin (G17). Poly(A) + RNA was extracted using a FastTrack 2.0 mRNA isolation kit (Invitrogen, The Netherlands), to obtain 2 mg from each of the U373 samples left untreated and also from the gastrintreated U373 samples. These samples were used to make driver and tester cDNA respectively. The suppression of subtractive hybridization was performed with the PCR-Select cDNA subtraction kit according to the manufacturer's instructions (Clontech, France). Brie¯y, driver and tester were digested with RsaI and the tester was ligated to adapter DNA.
After two hybridizations with the tester and driver cDNA (8 and 16 h), the resulting mixture was diluted 1 : 1000 and Hot Start ampli®ed with JumpStart Taq polymerase (Sigma, France) by means¯anking and nested primers to produce a subtracted and normalized PCR fragment library. Thirty primary and 20 secondary cycles of PCR ampli®cation yielded the greatest signal:noise ratio was estimated by comparing the¯uorescence of PCR product synthesized in a control subtraction provided in the kit. On the basis of these conditions, subtracted PCR products were TA-cloned into the pGEM-T Easy plasmid (Promega, France) transformed into E. Coli cells of the strain JM109 (Promega). Dierential screening was performed to eliminate falsely positive cases: 182 bacterial colonies were picked out at random and incubated for 2 h at 378C in 96-well plates containing 100 ml of LB-ampicilin medium. One microliter from each well containing growth medium was spotted on to duplicate Optitran 1 nitrocellulose membranes (Schleicher and Schuell, France). Each membrane was placed on an LB/agar plate containing ampicilin and incubated at 378C overnight. The colonies were then denatured by an alkaline treatment (0.5 M NaOH, 1.5 M NaCl) and neutralized with 0.5 M TrisHCl [pH 7.4], 1.5 M NaCl. The DNA was ®xed to nitrocellulose by baking for 2 h in an oven set at 808C. Each nitrocellulose membrane was hybridized to 32 P-radiolabelled cDNA probes (1610 7 c.p.m./ml) derived from either forward subtraction (cDNA from G17-treated cells as tester, and cDNA from untreated cells as driver) or reversesubtraction (cDNA from untreated cells as tester, and cDNA from G17-treated cells cDNA as driver). The membranes were exposed to Kodak BioMax MR X-ray ®lm for 24 h.
Sequencing and search in databases
DNA sequencing was performed by Genome Express (Grenoble, France). Homology searches were performed using the NCBI BLAST server (USA).
Quantitative competitive RT ± PCR
To quantify the mRNA for the S100A6, the tenascin-C and the MLCK genes in untreated and G17-treated cells we used the competitive RT ± PCR technique, in which the competitor was a truncated mRNA fragment of the gene of interest obtained by the in vitro transcription of a recombinant cDNA. We used the strategy previously described to synthesize the competitor RNA (Vande Heuvel et al., 1993) . To synthesize each competitor RNA, a PCR was performed with the following sense primers on a human brain cDNA library by means of a thermostable Taq DNA polymerase (Promega): S100A6.S: 5'cgaccgctcgcgtcgcatttggc3', Tenascin-C.S: 5'ccgggatcgccaatgcccaggg3', MLCK.S: 5'caggagattagcatcatgaactgc3', and the following antisense primers, which enabled less than 20% truncated-ampli®ed fragment to be obtained when compared to the native fragment: S100A6.AS: 5'agcaggcaatttacccaccactggatttgccctatttattttcagcccttg3'; Tenascin-C.AS: 5'agcagggcggcccgagacgcattgtccccaggcctgtgaagccctcg3'; MLCK.AS: 5'agcaggggagccacaaattctggggtgcccgcattctccagcctcct3'.
The program used was: 958C/3 min, (958C/45 s, 708C/45 s, 728C/1 min)635 cycles, 728C/5 min. Each recombinant cDNA was cloned into pGEM-T easy 1 plasmid (Promega). Each construction was linearized by SalI or SacII restriction enzyme (Promega) and transcribed using T7 RNA polymerase or SP6 RNA polymerase (Promega) according to the orientation of the fragment. DNA was subsequently digested for 15 min with 1 unit of RNase-free DNase RQ1 (Promega) per microgram of DNA at 378C. The synthesized competitor RNA was ®nally dissolved in water and quanti®ed by UVspectrophotometry. The integrity and the correct size of each competitor RNA and their integrity were checked on agarose formaldehyde gels and stored in aliquots at 7708C.
Eight reaction tubes containing the same amount of total RNA and eight serial threefold dilutions (1 pg to 3610 74 pg) of the competitor RNA were prepared for each condition, as were three control reactions containing total RNA only, competitor RNA only, or no matrix. Competitive RT ± PCR was performed by the one-step method Access RT ± PCR kit (Promega) by means of the sense primers described above, and the reverse primers of the sequences underlined in the reverse primer sequences were used to synthesize the competitor RNA. The following program was used: 488C/ 45 min, (948C/1 min, 608C/1 min, 688C/2 min)630 cycles, 688C/7 min. Ampli®cations in the respect of the conditions reported above enabled two amplicons to be obtained, one from the wild-type RNA and the other from the competitor. Amplicons from wild-type S100A6, tenascin-C and MLCK mRNA were respectively 398, 336 and 367 bp-long. Those from the competitor were 341, 271, and 323 bp-long respectively.
Quantification of mRNA
PCR products were separated on 3% ethidium bromidestained agarose gels in 16TBE. The intensity of the¯u orescence of the PCR products was determined on the basis of the Scion Image Software (NIH) by measuring the densitometry of the DNA bands from a negative photograph of the gel. The equivalence in¯uorescence of the two bands resulting from the competitive RT ± PCR was determined by plotting: log(the¯uorescence of the competitor product/thē uorescence of the wild-type cDNA)=f(log copies of the competitor RNA added) and the abscise value at the origin to give the number of mRNA molecules in the sample.
Transfection, CAT assay and luciferase assay
Reporter plasmids p2A9-CAT (containing the full-length S100A6 gene promoter), pTN1175-CAT, pTN220-CAT (containing respectively the (71175, +79) and the (7220, +79) tenascin-C promoter fused to Chloramphenicol Acetyl Transferase reporter gene (CAT)) and pTN865-Luc (containing the (7865, +38) tenascin-C promoter upstream the luciferase structural reporter gene (pGL3, Promega)) were used in transient expression analysis. Cells in 10 cm diameter petri dishes were transfected with 10 mg of each plasmid by means of Superfect transfection reagent (Qiagen, Les Ulis, France) according to the manufacturer's instructions. Twenty-four hours after transfection about 2.5610 5 cells were distributed into a 12-well plate. The cells were stimulated with tetradecanoyl phorbol acetate (TPA, Sigma) at 100 ng/ml or gastrin at 10 78 M. Chloramphenicol acetyltransferase (CAT) assays were performed with the CAT assay Elisa kit (Roche Molecular Biochemicals, Meylan, France) according to the manufacturer's instructions, with the optical density at 405 nm of each assay re¯ecting the CAT concentrations (mean of O.D units+s.d.). Luciferase activity of the cells transfected with a plasmid containing the luciferase reporter gene were treated as previously described (Astruc et al., 1995) .
